1	2-methoxyestradiol	2-methoxyestradiol	B-NP	NN	O	2	SUB	-1
2	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	18	inhibits
3	hypoxia-inducible	hypoxia-inducible	B-NP	JJ	O	5	NMOD	-1
4	factor	factor	I-NP	NN	O	5	NMOD	-1
5	1alpha	1alpha	I-NP	NN	O	11	NMOD	-1
6	,	,	O	,	O	11	P	-1
7	tumor	tumor	B-NP	NN	O	8	NMOD	-1
8	growth	growth	I-NP	NN	O	11	NMOD	4	growth
9	,	,	O	,	O	11	P	-1
10	and	and	O	CC	O	11	NMOD	-1
11	angiogenesis	angiogenesis	B-NP	NN	O	2	OBJ	3	angiogenesis
12	and	and	O	CC	O	2	VMOD	-1
13	augments	augment	B-VP	VBZ	O	2	VMOD	-1
14	paclitaxel	paclitaxel	B-NP	NN	O	15	NMOD	-1
15	efficacy	efficacy	I-NP	NN	O	13	OBJ	0
16	in	in	B-PP	IN	O	15	NMOD	-1
17	head	head	B-NP	NN	O	22	NMOD	-1
18	and	and	O	CC	O	22	NMOD	-1
19	neck	neck	B-NP	NN	O	22	NMOD	-1
20	squamous	squamous	I-NP	JJ	O	22	NMOD	-1
21	cell	cell	I-NP	NN	O	22	NMOD	-1
22	carcinoma	carcinoma	I-NP	NN	O	16	PMOD	-1
23	.	.	O	.	O	2	P	-1

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Head	Head	B-NP	NN	O	8	NMOD	-1
4	and	and	I-NP	CC	O	8	NMOD	-1
5	neck	neck	I-NP	NN	O	8	NMOD	-1
6	squamous	squamous	I-NP	JJ	O	8	NMOD	-1
7	cell	cell	I-NP	NN	O	8	NMOD	-1
8	carcinomas	carcinoma	I-NP	NNS	O	9	SUB	-1
9	have	have	B-VP	VBP	O	1	NMOD	-1
10	been	be	I-VP	VBN	O	9	VC	-1
11	reported	report	I-VP	VBN	O	10	VC	-1
12	to	to	I-VP	TO	O	13	VMOD	-1
13	overexpress	overexpress	I-VP	VB	O	11	VMOD	9	overexpress
14	hypoxia-inducible	hypoxia-inducible	B-NP	JJ	B-protein	15	NMOD	-1
15	factor	factor	I-NP	NN	I-protein	19	NMOD	-1
16	(	(	O	(	O	18	DEP	-1
17	HIF	HIF	B-NP	NN	B-protein	18	DEP	-1
18	)	)	O	)	O	15	NMOD	-1
19	-1alpha	-1alpha	B-NP	NN	O	23	NMOD	-1
20	,	,	O	,	O	23	P	-1
21	a	a	B-NP	DT	O	23	NMOD	-1
22	transcription	transcription	I-NP	NN	B-protein	23	NMOD	0
23	factor	factor	I-NP	NN	I-protein	13	OBJ	-1
24	that	that	B-NP	WDT	O	23	NMOD	-1
25	promotes	promote	B-VP	VBZ	O	24	SBAR	0
26	expression	expression	B-NP	NN	O	31	NMOD	0
27	of	of	B-PP	IN	O	26	NMOD	-1
28	angiogenesis	angiogenesis	B-NP	NN	B-protein	29	NMOD	3	angiogenesis
29	factors	factor	I-NP	NNS	I-protein	27	PMOD	-1
30	and	and	O	CC	O	31	NMOD	-1
31	resistance	resistance	B-NP	NN	O	25	OBJ	-1
32	to	to	B-PP	TO	O	31	NMOD	-1
33	programmed	program	B-NP	VBN	O	35	AMOD	-1
34	and	and	I-NP	CC	O	35	AMOD	-1
35	therapy-induced	therapy-induced	I-NP	JJ	O	37	NMOD	17	induced
36	cell	cell	I-NP	NN	O	37	NMOD	-1
37	death	death	I-NP	NN	O	32	PMOD	5	death
38	.	.	O	.	O	9	P	-1

1	2-Methoxyestradiol	2-Methoxyestradiol	B-NP	NN	O	5	SUB	-1
2	(	(	O	(	O	4	DEP	-1
3	2ME2	2ME2	B-NP	NN	B-protein	4	DEP	-1
4	)	)	O	)	O	1	NMOD	-1
5	is	be	B-VP	VBZ	O	0	ROOT	-1
6	a	a	B-NP	DT	O	8	NMOD	-1
7	natural	natural	I-NP	JJ	O	8	NMOD	-1
8	compound	compound	I-NP	NN	O	5	PRD	-1
9	with	with	B-PP	IN	O	8	NMOD	-1
10	HIF-1alpha	HIF-1alpha	B-NP	NN	B-protein	12	NMOD	-1
11	inhibitory	inhibitory	I-NP	JJ	O	12	NMOD	18	inhibitory
12	activity	activity	I-NP	NN	O	9	PMOD	0
13	that	that	B-NP	WDT	O	8	NMOD	-1
14	is	be	B-VP	VBZ	O	13	SBAR	-1
15	currently	currently	I-VP	RB	O	14	VMOD	-1
16	being	be	I-VP	VBG	O	14	VC	-1
17	evaluated	evaluate	I-VP	VBN	O	16	VC	-1
18	in	in	B-PP	IN	O	17	VMOD	-1
19	phase	phase	B-NP	NN	O	24	NMOD	-1
20	1	1	I-NP	CD	O	24	NMOD	-1
21	and	and	I-NP	CC	O	24	NMOD	-1
22	2	2	I-NP	CD	O	24	NMOD	-1
23	clinical	clinical	I-NP	JJ	O	24	NMOD	-1
24	trials	trial	I-NP	NNS	O	18	PMOD	-1
25	for	for	B-PP	IN	O	24	NMOD	-1
26	advanced	advance	B-NP	VBN	O	28	NMOD	-1
27	solid	solid	I-NP	JJ	O	28	NMOD	-1
28	tumors	tumor	I-NP	NNS	O	31	NMOD	-1
29	and	and	O	CC	O	31	NMOD	-1
30	multiple	multiple	B-NP	JJ	O	31	NMOD	-1
31	myeloma	myeloma	I-NP	NN	O	25	PMOD	-1
32	.	.	O	.	O	5	P	-1

1	To	To	B-PP	TO	O	6	VMOD	-1
2	our	our	B-NP	PRP$	O	3	NMOD	-1
3	knowledge	knowledge	I-NP	NN	O	1	PMOD	-1
4	,	,	O	,	O	6	P	-1
5	this	this	B-NP	DT	O	6	SUB	-1
6	is	be	B-VP	VBZ	O	0	ROOT	-1
7	the	the	B-NP	DT	O	9	NMOD	-1
8	first	first	I-NP	JJ	O	9	NMOD	-1
9	study	study	I-NP	NN	O	6	PRD	-1
10	to	to	B-VP	TO	O	11	VMOD	-1
11	evaluate	evaluate	I-VP	VB	O	9	NMOD	-1
12	the	the	B-NP	DT	O	13	NMOD	-1
13	effects	effect	I-NP	NNS	O	11	OBJ	16	effects
14	of	of	B-PP	IN	O	13	NMOD	-1
15	2ME2	2ME2	B-NP	NN	B-protein	14	PMOD	-1
16	in	in	B-PP	IN	O	13	NMOD	-1
17	head	head	B-NP	NN	O	22	NMOD	-1
18	and	and	O	CC	O	22	NMOD	-1
19	neck	neck	B-NP	NN	O	22	NMOD	-1
20	squamous	squamous	I-NP	JJ	O	22	NMOD	-1
21	cell	cell	I-NP	NN	O	22	NMOD	-1
22	carcinoma	carcinoma	I-NP	NN	O	16	PMOD	-1
23	.	.	O	.	O	6	P	-1

1	EXPERIMENTAL	EXPERIMENTAL	B-NP	JJ	O	2	NMOD	-1
2	DESIGN	DESIGN	I-NP	NN	O	10	VMOD	-1
3	:	:	O	:	O	2	P	-1
4	In	In	B-PP	IN	O	2	NMOD	-1
5	the	the	B-NP	DT	O	7	NMOD	-1
6	present	present	I-NP	JJ	O	7	NMOD	0
7	study	study	I-NP	NN	O	4	PMOD	-1
8	,	,	O	,	O	10	P	-1
9	we	we	B-NP	PRP	O	10	SUB	-1
10	investigated	investigate	B-VP	VBD	O	0	ROOT	-1
11	the	the	B-NP	DT	O	12	NMOD	-1
12	effects	effect	I-NP	NNS	O	10	OBJ	16	effects
13	of	of	B-PP	IN	O	12	NMOD	-1
14	2ME2	2ME2	B-NP	NN	B-protein	13	PMOD	-1
15	alone	alone	B-ADVP	RB	O	14	NMOD	-1
16	and	and	O	CC	O	13	PMOD	-1
17	in	in	B-PP	IN	O	13	PMOD	-1
18	combination	combination	B-NP	NN	O	17	PMOD	-1
19	with	with	B-PP	IN	O	18	NMOD	-1
20	paclitaxel	paclitaxel	B-NP	NN	O	24	NMOD	-1
21	,	,	O	,	O	24	P	-1
22	an	an	B-NP	DT	O	24	NMOD	-1
23	active	active	I-NP	JJ	O	24	NMOD	-1
24	agent	agent	I-NP	NN	O	19	PMOD	-1
25	in	in	B-PP	IN	O	24	NMOD	-1
26	recurrent	recurrent	B-NP	JJ	O	34	NMOD	-1
27	or	or	I-NP	CC	O	34	NMOD	-1
28	advanced	advanced	I-NP	JJ	O	29	NMOD	-1
29	head	head	I-NP	NN	O	34	NMOD	-1
30	and	and	I-NP	CC	O	34	NMOD	-1
31	neck	neck	I-NP	NN	O	34	NMOD	-1
32	squamous	squamous	I-NP	JJ	O	34	NMOD	-1
33	cell	cell	I-NP	NN	O	34	NMOD	-1
34	carcinoma	carcinoma	I-NP	NN	O	25	PMOD	-1
35	.	.	O	.	O	10	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	2ME2	2ME2	B-NP	NN	O	4	SUB	-1
4	exhibited	exhibit	B-VP	VBD	O	1	NMOD	16	exhibited
5	antiproliferative	antiproliferative	B-NP	JJ	O	8	NMOD	-1
6	and	and	I-NP	CC	O	8	NMOD	-1
7	cytotoxic	cytotoxic	I-NP	JJ	O	8	NMOD	-1
8	effects	effect	I-NP	NNS	O	4	OBJ	0
9	in	in	B-PP	IN	O	4	VMOD	-1
10	a	a	B-NP	DT	O	11	NMOD	-1
11	panel	panel	I-NP	NN	O	9	PMOD	-1
12	of	of	B-PP	IN	O	11	NMOD	-1
13	five	five	B-NP	CD	O	14	NMOD	-1
14	head	head	I-NP	NN	O	21	NMOD	-1
15	and	and	O	CC	O	21	NMOD	-1
16	neck	neck	B-NP	NN	O	21	NMOD	-1
17	squamous	squamous	I-NP	JJ	O	21	NMOD	-1
18	cell	cell	I-NP	NN	O	21	NMOD	-1
19	carcinoma	carcinoma	I-NP	NN	O	21	NMOD	-1
20	cell	cell	I-NP	NN	O	21	NMOD	-1
21	lines	line	I-NP	NNS	O	12	PMOD	-1
22	in	in	B-PP	IN	O	4	VMOD	-1
23	the	the	B-NP	DT	O	28	NMOD	-1
24	0.5	0.5	I-NP	CD	O	26	AMOD	-1
25	to	to	I-NP	TO	O	26	AMOD	-1
26	10	10	I-NP	CD	O	28	NMOD	-1
27	micromol/L	micromol/L	I-NP	NN	O	28	NMOD	-1
28	range	range	I-NP	NN	O	22	PMOD	-1
29	,	,	O	,	O	28	P	-1
30	including	include	B-PP	VBG	O	28	NMOD	-1
31	induction	induction	B-NP	NN	O	30	PMOD	17	induction
32	of	of	B-PP	IN	O	31	NMOD	-1
33	G2-M	G2-M	B-NP	NN	O	34	NMOD	-1
34	blockade	blockade	I-NP	NN	O	40	NMOD	0
35	,	,	O	,	O	40	P	-1
36	caspase-3/7	caspase-3/7	B-NP	NN	B-protein	37	NMOD	-1
37	activation	activation	I-NP	NN	O	40	NMOD	17	activation
38	,	,	O	,	O	40	P	-1
39	and	and	O	CC	O	40	NMOD	-1
40	apoptosis	apoptosis	B-NP	NN	O	32	PMOD	5	apoptosis
41	at	at	B-PP	IN	O	31	NMOD	-1
42	48	48	B-NP	CD	O	43	NMOD	-1
43	hours	hour	I-NP	NNS	O	41	PMOD	-1
44	.	.	O	.	O	1	P	-1

1	2ME2	2ME2	B-NP	NN	O	2	SUB	-1
2	resulted	result	B-VP	VBD	O	0	ROOT	0
3	in	in	B-PP	IN	O	2	VMOD	-1
4	decreased	decrease	B-NP	VBN	O	7	NMOD	18	decreased
5	nuclear	nuclear	I-NP	JJ	O	7	NMOD	-1
6	HIF-1alpha-binding	HIF-1alpha-binding	I-NP	JJ	O	7	NMOD	15	binding
7	activity	activity	I-NP	NN	O	3	PMOD	0
8	and	and	O	CC	O	2	VMOD	-1
9	affected	affect	B-VP	VBD	O	2	VMOD	16	affected
10	the	the	B-NP	DT	O	11	NMOD	-1
11	expression	expression	I-NP	NN	O	9	OBJ	9	expression
12	of	of	B-PP	IN	O	11	NMOD	-1
13	downstream	downstream	B-NP	JJ	B-DNA	14	NMOD	0
14	genes	gene	I-NP	NNS	I-DNA	12	PMOD	-1
15	,	,	O	,	O	14	P	-1
16	such	such	B-PP	JJ	O	17	PMOD	-1
17	as	as	I-PP	IN	O	14	NMOD	-1
18	bid	bid	B-NP	NN	O	34	NMOD	-1
19	,	,	O	,	O	34	P	-1
20	a	a	B-NP	DT	O	24	NMOD	-1
21	proapoptotic	proapoptotic	I-NP	JJ	B-protein	24	NMOD	-1
22	bcl-2	bcl-2	I-NP	NN	I-protein	24	NMOD	-1
23	family	family	I-NP	NN	I-protein	24	NMOD	-1
24	member	member	I-NP	NN	I-protein	34	NMOD	-1
25	,	,	O	,	O	34	P	-1
26	and	and	O	CC	O	34	NMOD	-1
27	vascular	vascular	B-NP	JJ	B-protein	30	NMOD	-1
28	endothelial	endothelial	I-NP	JJ	I-protein	30	NMOD	-1
29	growth	growth	I-NP	NN	I-protein	30	NMOD	0
30	factor	factor	I-NP	NN	I-protein	34	NMOD	-1
31	,	,	O	,	O	34	P	-1
32	a	a	B-NP	DT	O	34	NMOD	-1
33	proangiogenic	proangiogenic	I-NP	JJ	B-protein	34	NMOD	3	angiogenic
34	cytokine	cytokine	I-NP	NN	I-protein	17	PMOD	-1
35	.	.	O	.	O	2	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	up-regulation	up-regulation	I-NP	NN	O	18	NMOD	17	up-regulation
3	of	of	B-PP	IN	O	2	NMOD	-1
4	Bid	Bid	B-NP	NN	B-protein	3	PMOD	-1
5	(	(	O	(	O	16	DEP	-1
6	57.5	57.5	B-NP	CD	O	7	NMOD	-1
7	%	%	I-NP	NN	O	12	NMOD	-1
8	at	at	B-PP	IN	O	7	NMOD	-1
9	12	12	B-NP	CD	O	10	NMOD	-1
10	hours	hour	I-NP	NNS	O	8	PMOD	-1
11	,	,	O	,	O	12	P	-1
12	P	P	B-NP	NN	O	16	DEP	-1
13	less	less	B-ADJP	JJR	O	12	NMOD	-1
14	than	than	B-PP	IN	O	13	AMOD	-1
15	0.0006	0.0006	B-NP	CD	O	14	PMOD	-1
16	)	)	O	)	O	4	NMOD	-1
17	and	and	O	CC	O	18	NMOD	-1
18	inhibition	inhibition	B-NP	NN	O	49	SUB	18	inhibition
19	of	of	B-PP	IN	O	18	NMOD	-1
20	vascular	vascular	B-NP	JJ	B-protein	24	NMOD	-1
21	endothelial	endothelial	I-NP	JJ	I-protein	24	NMOD	-1
22	growth	growth	I-NP	NN	I-protein	24	NMOD	0
23	factor	factor	I-NP	NN	I-protein	24	NMOD	-1
24	secretion	secretion	I-NP	NN	O	19	PMOD	14	secretion
25	(	(	O	(	O	48	DEP	-1
26	57.7	57.7	B-NP	CD	O	27	NMOD	-1
27	%	%	I-NP	NN	O	32	NMOD	-1
28	at	at	B-PP	IN	O	27	NMOD	-1
29	24	24	B-NP	CD	O	30	NMOD	-1
30	hours	hour	I-NP	NNS	O	28	PMOD	-1
31	,	,	O	,	O	32	P	-1
32	P	P	B-NP	NN	O	39	NMOD	-1
33	less	less	B-ADJP	JJR	O	32	NMOD	-1
34	than	than	B-PP	IN	O	33	AMOD	-1
35	0.015	0.015	B-NP	CD	O	34	PMOD	-1
36	;	;	O	:	O	39	P	-1
37	and	and	O	CC	O	39	NMOD	-1
38	50.3	50.3	B-NP	CD	O	39	NMOD	-1
39	%	%	I-NP	NN	O	44	NMOD	-1
40	at	at	B-PP	IN	O	39	NMOD	-1
41	48	48	B-NP	CD	O	42	NMOD	-1
42	hours	hour	I-NP	NNS	O	40	PMOD	-1
43	,	,	O	,	O	44	P	-1
44	P	P	B-NP	NN	O	46	SUB	-1
45	less	less	B-ADJP	JJR	O	46	AMOD	-1
46	than	than	B-PP	IN	O	48	DEP	-1
47	0.0006	0.0006	B-NP	CD	O	46	AMOD	-1
48	)	)	O	)	O	24	NMOD	-1
49	could	could	B-VP	MD	O	0	ROOT	-1
50	be	be	I-VP	VB	O	49	VC	-1
51	partially	partially	I-VP	RB	O	50	VMOD	-1
52	attributed	attribute	I-VP	VBN	O	50	VC	-1
53	to	to	B-PP	TO	O	52	VMOD	-1
54	the	the	B-NP	DT	O	55	NMOD	-1
55	effects	effect	I-NP	NNS	O	53	PMOD	16	effects
56	on	on	B-PP	IN	O	55	NMOD	-1
57	HIF-1alpha	HIF-1alpha	B-NP	NN	B-protein	56	PMOD	-1
58	,	,	O	,	O	49	P	-1
59	because	because	B-SBAR	IN	O	49	VMOD	-1
60	HIF-1alpha	HIF-1alpha	B-NP	NN	B-RNA	63	NMOD	-1
61	small	small	B-NP	JJ	I-RNA	63	NMOD	-1
62	interfering	interfere	I-NP	VBG	I-RNA	63	NMOD	-1
63	RNAs	RNA	I-NP	NNS	I-RNA	64	SUB	-1
64	produced	produce	B-VP	VBD	O	59	SBAR	0
65	similar	similar	B-NP	JJ	O	66	NMOD	-1
66	effects	effect	I-NP	NNS	O	64	OBJ	0
67	.	.	O	.	O	49	P	-1

1	Finally	Finally	B-ADVP	RB	O	22	VMOD	-1
2	,	,	O	,	O	22	P	-1
3	in	in	B-ADVP	FW	O	22	VMOD	-1
4	vivo	vivo	I-ADVP	FW	O	3	AMOD	-1
5	,	,	O	,	O	22	P	-1
6	in	in	B-PP	IN	O	22	VMOD	-1
7	a	a	B-NP	DT	O	9	NMOD	-1
8	xenograft	xenograft	I-NP	NN	O	9	NMOD	-1
9	model	model	I-NP	NN	O	6	PMOD	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	head	head	B-NP	NN	O	16	NMOD	-1
12	and	and	I-NP	CC	O	16	NMOD	-1
13	neck	neck	I-NP	NN	O	16	NMOD	-1
14	squamous	squamous	I-NP	JJ	O	16	NMOD	-1
15	cell	cell	I-NP	NN	O	16	NMOD	-1
16	carcinoma	carcinoma	I-NP	NN	O	10	PMOD	-1
17	using	use	B-VP	VBG	O	16	NMOD	-1
18	UM-SCC-11A	UM-SCC-11A	B-NP	NN	B-cell_line	19	NMOD	-1
19	cells	cell	I-NP	NNS	I-cell_line	17	OBJ	-1
20	,	,	O	,	O	22	P	-1
21	2ME2	2ME2	B-NP	NN	O	22	SUB	-1
22	exhibited	exhibit	B-VP	VBD	O	0	ROOT	0
23	antitumor	antitumor	B-NP	JJ	O	25	AMOD	-1
24	and	and	I-NP	CC	O	25	AMOD	-1
25	antiangiogenic	antiangiogenic	I-NP	JJ	O	26	NMOD	3	angiogenic
26	activity	activity	I-NP	NN	O	22	OBJ	18	activity
27	,	,	O	,	O	22	P	-1
28	as	as	B-SBAR	IN	O	22	VMOD	-1
29	measured	measure	B-VP	VBN	O	28	SBAR	-1
30	by	by	B-PP	IN	O	29	VMOD	-1
31	CD31	CD31	B-NP	NN	B-protein	32	NMOD	-1
32	immunostaining	immunostaining	I-NP	NN	O	30	PMOD	-1
33	.	.	O	.	O	22	P	-1

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	These	These	B-NP	DT	O	4	NMOD	-1
4	results	result	I-NP	NNS	O	5	SUB	0
5	provide	provide	B-VP	VBP	O	1	NMOD	-1
6	support	support	B-NP	NN	O	5	OBJ	0
7	for	for	B-PP	IN	O	6	NMOD	-1
8	the	the	B-NP	DT	O	9	NMOD	-1
9	use	use	I-NP	NN	O	7	PMOD	0
10	of	of	B-PP	IN	O	9	NMOD	-1
11	2ME2	2ME2	B-NP	NN	B-protein	10	PMOD	-1
12	in	in	B-PP	IN	O	6	NMOD	-1
13	combination	combination	B-NP	NN	O	12	PMOD	-1
14	with	with	B-PP	IN	O	13	NMOD	-1
15	paclitaxel	paclitaxel	B-NP	NN	O	14	PMOD	-1
16	for	for	B-PP	IN	O	15	NMOD	-1
17	the	the	B-NP	DT	O	18	NMOD	-1
18	treatment	treatment	I-NP	NN	O	16	PMOD	19	treatment
19	of	of	B-PP	IN	O	18	NMOD	-1
20	recurrent	recurrent	B-NP	JJ	O	28	NMOD	-1
21	or	or	I-NP	CC	O	28	NMOD	-1
22	advanced	advanced	I-NP	JJ	O	23	NMOD	-1
23	head	head	I-NP	NN	O	28	NMOD	-1
24	and	and	I-NP	CC	O	28	NMOD	-1
25	neck	neck	I-NP	NN	O	28	NMOD	-1
26	squamous	squamous	I-NP	JJ	O	28	NMOD	-1
27	cell	cell	I-NP	NN	O	28	NMOD	-1
28	carcinoma	carcinoma	I-NP	NN	O	19	PMOD	-1
29	.	.	O	.	O	1	P	-1

